William R. Rohn - Chairman
William R. Rohn joined our board of directors as the chairman in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. Mr. Rohn also held various management positions with IDEC Pharmaceuticals, a biotechnology company, including: President and Chief Operating Officer from 1998 to 2003, Senior Vice President, Commercial Operations from 1996 to 1998 and Senior Vice President, Commercial and Corporate Development from 1993 to 1996. He also held various management positions with Adria Laboratories, a pharmaceutical company acquired by Pfizer Inc., including: Senior Vice President of Commercial Operations from 1991 to 1993 and Vice President of Business Development and Licensing from 1985 to 1990. Mr. Rohn currently serves on the board of directors of Hansen Medical, Inc., a medical device company. Mr. Rohn previously served on the boards of Intellikine, Inc., a pharmaceutical company acquired by Takeda America Holdings, Inc., Cerus Corporation, a biomedical products company, Elan Corporation, plc, a pharmaceutical company acquired by Perrigo Company plc, Metabasis Therapeutics, Inc., a biopharmaceutical company that merged with Ligand Pharmaceuticals Inc., and Pharmacyclics Inc., a pharmaceutical company. Mr. Rohn holds a Bachelor’s degree in Marketing from Michigan State University and has completed graduate-level coursework in Business Administration at Indiana State University.
Phillip M. Schneider, M.B.A
Phillip M. Schneider joined our board in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. He currently serves as a member of the board of directors of Arena Pharmaceuticals Corporation, a pharmaceutical company, which he joined in 2008, and Auspex Pharmaceuticals, a pharmaceutical company, which he joined in 2014. He previously served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 to 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
James C. Gale
James Gale has served as a member of our board of directors since 2009. Since 1998, Mr. Gale has served as the founding partner and a managing director of Signet Healthcare Partners, a private equity firm that invests in commercial stage healthcare companies, and an affiliate of SMH Capital, Inc. Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC from 1992 to 1998. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent from 1989 to 1992. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co., an investment bank. He serves as a member of the board of directors of two public companies, IGI Laboratories, Inc. and Knight Therapeutics Inc., as well as several private companies. During the past five years, he also served on the board of directors of two additional public companies, Paladin Labs Inc. and Octoplus BV. Mr. Gale holds a Bachelor’s degree in Education from the University of Arizona and an M.B.A. from the University of Chicago.
Kenneth Van Heel
Kenneth Van Heel joined our board of directors in 2012. Since 2007, Mr. Van Heel has served as Global Director of Portfolio Investments and Director of Dow Chemical Canada Pension Plan at The Dow Chemical Company, a chemicals manufacturer, and has held various positions with Dow and its wholly-owned subsidiaries, including: Senior Manager of Private Equity of The Dow Chemical Company from 2003 to 2006, Manager of Dow Corporate Venture Capital from 2000 until 2003 and other various positions with Dow since 1994. Mr. Van Heel holds a Bachelor’s degree in Materials Science and Engineering from Illinois Institute of Technology and an M.B.A. from DePaul University.
Bertrand C. Liang, M.D., Ph.D., M.B.A.
Dr. Bertrand C. Liang is the Managing and Executive Director of LCC Ventures, an advisory company in the biotech, pharma and venture areas.
He was previously Vice Chairman, Paramount Biosciences, LLC, where he led the private equity activities, including licensing, investments and internal development capabilities of the seven global offices, from Shanghai to London. He was President, CEO and Director of Tracon Pharmaceuticals, Inc., an oncology-focused development company located in San Diego; previously, he was Vice President, New Ventures at Biogen Idec.
Prior to the merger of the Biogen and Idec companies, he was Vice President, Development, managing the Hematology and Oncology portfolio, including biologics such as Rituxan and Zevalin, as well as small molecules. Subsequent to the merger, he became the Site Head of Development (preclinical and clinical) in San Diego prior to being in the corporate venture capital group, which was partnered with MPM Capital, one of the largest global life science focused funds. Dr. Liang joined Idec from Amgen, where he led the development of various cytokines and proteins, including the clinical development and launch of Neulasta™ (pegfilgrastim), whose sales have reached over $8B since introduction to the market in 2002.
Dr. Liang served as study section member as well as section chair (metastatic cancer) of a NCI Organizational Review Group (Brain Tumors), which evaluated all programs within the NCI and set recommendations for future direction of resource allocation for the institute. Dr. Liang serves on the Board of Directors for several companies, including Tracon Pharmaceuticals, Asphelia Pharma, and Pico Pharmaceuticals.
Dr. Liang is clinically trained in Neurology and Oncology, with basic science work in molecular genetics and molecular pharmacology. Dr. Liang has held academic positions at the NCI, University of Colorado and University of Vermont, where he was the head of Human Medical Genetics. His previous research involved the role of mitochondria and the mitochondrial genome in the tumorigenic phenotype, translational research in cancer and neurology patients, and patented platform technology work in genomics discovery.